US 9937207
Targeted disruption of T cell receptor genes using talens
granted A61KA61K2239/38A61K2239/48
Quick answer
US patent 9937207 (Targeted disruption of T cell receptor genes using talens) held by Sangamo Therapeutics, Inc. expires Mon Apr 05 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Sangamo Therapeutics, Inc.
- Grant date
- Tue Apr 10 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Apr 05 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 13
- CPC classes
- A61K, A61K2239/38, A61K2239/48, A61K35/26, A61K40/11